-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA AUTHORIZES LYNCH REGENERATIVE MEDICINE'S IND FOR A PHASE IIB CLINICAL TRIAL FOR INJECTION OF RHPDGF-BB FOR TREATMENT OF INFRAORBITAL HOLLOWING

Reuters·10/21/2026 13:00:07